SCHEMBL399014

SCHEMBL399014

O=C(c1cccc(S(=O)(=O)Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 6/20 0.64
L3MBTL1 Q9Y468 6/20 0.64
PKM P14618 1/20 0.61
RAB9A P51151 1/20 0.61
POLB P06746 1/20 0.60
L3MBTL4 Q8NA19 2/20 0.59
MBTD1 Q05BQ5 2/20 0.59
CHRM2 P08172 1/20 0.59
CHRM4 P08173 1/20 0.59
CHRM5 P08912 1/20 0.59
CHRM1 P11229 1/20 0.59
ADRA2C P18825 1/20 0.59
CHRM3 P20309 1/20 0.59
OPRK1 P41145 1/20 0.59
TP53BP1 Q12888 1/20 0.59
PHF20 Q9BVI0 1/20 0.59
MORF4L1 Q9UBU8 1/20 0.59
ALDH1A1 P00352 2/20 0.59
CACNA1H O95180 1/20 0.57
TDP1 Q9NUW8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL399296 0.91 L3MBTL1 (0.77) L3MBTL3L3MBTL1PKMRAB9APOLB
SCHEMBL398558 0.90 L3MBTL1 (0.75) L3MBTL3L3MBTL1PKMRAB9APOLB
SCHEMBL399293 0.90 POLB (0.74) L3MBTL3L3MBTL1PKMRAB9APOLB
SCHEMBL398692 0.89 POLB (0.72) L3MBTL3L3MBTL1PKMRAB9APOLB
SCHEMBL397752 0.88 ALDH1A1 (0.66) L3MBTL3L3MBTL1PKMRAB9APOLB
SCHEMBL397972 0.87 ALDH1A1 (0.80) L3MBTL3L3MBTL1PKMRAB9APOLB
SCHEMBL397289 0.87 ALDH1A1 (0.68) L3MBTL3L3MBTL1PKMRAB9APOLB
SCHEMBL397957 0.85 CACNA1H (0.78) L3MBTL3L3MBTL1POLBL3MBTL4MBTD1
SCHEMBL395930 0.85 CACNA1H (0.76) L3MBTL3L3MBTL1POLBL3MBTL4MBTD1
SCHEMBL12027 0.80 LMNA (0.80) L3MBTL1PKMRAB9APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102282131-B As the new benzsulfamide of calcium ion channel blockor ABBVIE INC. (BS) 2015-08-26 CN claimed
EP-2382191-B1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE BAHAMAS LTD (BS) 2014-11-12 EP claimed
US-20130210827-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-08-15 US claimed
US-8404719-B2 Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers ABBVIE INC. (US) 2013-03-26 US claimed
US-20120083499-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2012-04-05 US claimed
US-20100197693-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-08-05 US claimed
CN-102282131-B As the new benzsulfamide of calcium ion channel blockor ABBVIE INC. (BS) 2015-08-26 CN disclosed
EP-2382191-B1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE BAHAMAS LTD (BS) 2014-11-12 EP disclosed
US-8741899-B2 (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof ABBVIE INC. (US) 2014-06-03 US disclosed
US-20130210827-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-08-15 US disclosed
US-8404719-B2 Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers ABBVIE INC. (US) 2013-03-26 US disclosed
US-20120083499-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2012-04-05 US disclosed
US-8101614-B2 Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers ABBOTT LABORATORIES (US) 2012-01-24 US disclosed
US-20100197693-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210827-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS CACNA1E, RYR2, RYR1 L3MBTL3 2063/4885L3MBTL1 1498/4885PKM 3099/4885
US-20120083499-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS CACNA1E, RYR2, RYR1 L3MBTL3 2063/4885L3MBTL1 1498/4885PKM 3099/4885
US-20100197693-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS CACNA1E, RYR2, RYR1 L3MBTL3 2063/4885L3MBTL1 1498/4885PKM 3099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.